KRAS and small cell lung carcinoma: Kras-activating mutation-driven genetically engineered mouse models (GEMMs) accurately reflect the biology of NSCLC with a mesenchymal profile, whereas Rb/p53 deletion produces tumors with NE-type SCLC features6,7.